Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
The securities were offered pursuant to an effective shelf registrationstatement filed by Cardium with the U.S. Securities and Exchange Commission.This press release does not constitute an offer to sell or the solicitation ofan offer to buy, and these securities may not be sold in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior to registrationor qualification under the securities laws of any such jurisdiction.
Advertisement
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc.and the Tissue Repair Company, are medical technology companies primarilyfocused on the development, manufacture and sale of innovative therapeuticproducts and devices for cardiovascular, ischemic and related indications.Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec,Ad5FGF-4), is a DNA-based growth factor therapeutic being developed forpotential use by interventional cardiologists as a one-time treatment topromote and stimulate the growth of collateral circulation in the hearts ofpatients with ischemic conditions such as recurrent angina. For moreinformation about Cardium Therapeutics and its businesses, products andtherapeutic candidates, please visit http://www.cardiumthx.com or view its2006 Annual Report athttp://www.cardiumthx.com/flash/pdf/2006CardiumAnnualReport.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medicaltechnology company in the emerging field of temperature modulation therapy torapidly and controllably cool the body in order to reduce cell death anddamage following acute ischemic events such as cardiac arrest or stroke, andto potentially lessen or prevent associated injuries such as adverseneurological outcomes. For more information about Cardium's InnerCoolsubsidiary and therapeutic hypothermia, including InnerCool's Celsius ControlSystem(TM), which has received regulatory clearance in the U.S., Europe andAustralia, and its CoolBlue(TM) surface-based system, which is currently beingmarketed in the U.S., please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-basedbiopharmaceutical company focused on the development of growth factortherapeutics for the treatment of severe chronic diabetic wounds. TRC's leadproduct candidate, Excellarate(TM), is a DNA-activated collagen gel fortopical treatment formulated with an adenovector delivery carrier encodinghuman platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) isinitially being developed to be administered once or twice for the potentialtreatment of non-healing diabetic foot ulcers. Other potential applicationsfor TRC's Gene Activated Matrix(TM) (GAM) technology include therapeuticangiogenesis (cardiovascular ischemia, peripheral arterial disease) andorthopedic products, including hard tissue (bone) and soft tissue (ligament,tendon, cartilage) repair. For more information about
